COA Patient Advocacy Network Drug Shortages, Oral Chemotherapy Orlando, 3-22-13 1Community Oncology Alliance.

Slides:



Advertisements
Similar presentations
Progress Against Ovarian Cancer. 1970–1979 Progress Against Ovarian Cancer 1970– : First effective combination chemotherapy regimen for ovarian.
Advertisements

EMS – Not a drug free zone. TETAF EMS Leadership Series Ed Racht, MD Chief Medical Officer AMR Medicine.
Workshop 2 Supply reasons Reasons for medicines shortages.
Workshop 2 Supply reasons Solutions for medicines shortages.
Critical Drug Shortages: A Major Public Health Problem That Affects Us All and How To Deal With It Philip M. Rosoff, M.D., M.A. Professor of Pediatrics.
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
Wednesday, December 17, :00pm-4:30pm EST National Coalition for Cancer Survivorship Post-Training Webinar ©2014 National Coalition for Cancer Survivorship.
E-HIM ™ : It Will Transform Your Job! By Beth Hjort, RHIA, CHP National Health Information and Technology Week November 7–13, 2004.
F.D.A. Revokes Approval of Avastin for Use as Breast Cancer Drug Andrew Pollack NY Times November 18, 2011
Christine Simmon Senior Vice President, Policy & Strategic Alliances Generic Pharmaceutical Association November 6, 2014 Biologics Naming.
An overview of off-label drug use Ignoring the Label Samantha Rue.
COC ADVOCACY TRACK Overview of National Oncology Issues & Key COA Initiatives for 2015 Ted Okon Orlando, Florida April 23, 2015.
DRUG SHORTAGES A PUBLIC HEALTH CRISIS. BACKGROUND  U.S Healthcare System is experiencing an alarming increase in number of drug shortages causing a major.
By: Fiona Lane. History The AHA was founded in 1898 The AHA provides education for health care leaders and is a source of information on health care issues.
© 2010 Premier, Inc. 9/8/ NAVIGATING THE DRUG SHORTAGE CRISIS IN AMERICAN HEALTHCARE Coleen A. Cherici, RPh, MBA Director of Pharmacy Consulting.
1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
P R E S E N T E D B Y: Carol Goularte Pharmacy Buyer Sierra Nevada Memorial Hospital August 19, 2009 Pharmaceutical Recall Process.
Pharmacovigilance obligations of the Pharmaceutical companies in India
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Key Facts about Drug Shortages Newly identified drug shortages have tripled from 61 in 2005 to 178 in By December 2011 they had already topped 200.
LEADERSHIP FLY-IN Washington, D.C. June 26-28, 2012 US GAPP LEADERSHIP FLY-IN Washington, D.C. June 26-28, 2012 US GAPP.
Communication is the Key Pharmacy Purchasing Pearls Marvin Finnefrock, PharmD Steven L. Gratch, Pharm. B.Sc., R.Ph. Diane Daskey Joanie MacIntosh, CPhT.
“Improving opioid availability through advocacy” Experience from Serbia Snežana Bošnjak International Pain Policy Fellow ( ) Institute for Oncology.
Community Oncology Conference Ricky Newton, CPA Director of Financial Services and Operations and Treasurer April 24, 2015.
Overviews of the Drug Distribution System & Barriers to Opioid Availability Dr. Bishnu Dutta Paudel International Pain Policy Fellowship Training Program.
The Changing Reimbursement System: Interaction Between Medicare Part B and Medicare Part D The intersection of business strategy and public policy.
Zambia’s Porous Borders & the Influx of Medicines.
Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.
The Power of the Rare Disease Community… Diane Dorman Vice President, Public Policy National Organization for Rare Disorders (NORD) 1 st International.
Calculating Oral Dosage
Center for Drug Evaluation and Research (CDER) Tanya Eberle Kamal Diar David Clements.
Community Oncology Conference Ricky Newton, CPA Director of Financial Services and Operations and Treasurer April 24, 2015.
Thomas Eingle, R.Ph. Inpatient Pharmacy Supervisor James A. Haley Veterans Hospital, Tampa, Fl.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
Quality & Safety of Generic Drugs in the World Market World Bank Conference “Good Intentions – Bad Drugs” March 10, 2005 Washington, D.C. Christine Simmon.
What HIT Policy Changes Will Mean for MedTech October 22, 2004 Blair Childs Executive Vice President, Strategic Planning & Implementation.
The Oncology Drug Shortage
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Program Coordinator Medication Assistance Program Smilow Cancer.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
© 2014 GS1 US ALL RIGHTS RESERVED Making a Difference 1.
Understanding Health Care Policy
Drug shortages By Mario Motta, MD.
“Running On Empty” Safe Medication Practices
Industry Perspective: Expanded Access Programs
Finland, a Global Testbed for Personalized Cancer Research?
An Increasing Demand for Prescription Drugs Drives Profitability
The Cancer Incidence Rate
Community Oncology 101: WHY DOES SITE OF SERVICE MATTER?
Cost-Efficiency of Medication Safety Program at Public Hospital, Riyadh, Saudi Arabia Yousef Ahmed Alomi, Mona Awad Alanazi, Radi Abdullah Alattyh, Fatimah.
Presentation transcript:

COA Patient Advocacy Network Drug Shortages, Oral Chemotherapy Orlando, Community Oncology Alliance

Drug Shortages as dangerous as a Florida Alligator 2Community Oncology Alliance

Chemotherapy Drug Shortages What? When? Where? Why? Who?

The What? FDA lists 122 drugs in short supply, are used in cancer care All are generic, “low cost” products

5Community Oncology Alliance

122 Drugs in short supply  Drug Shortages Drug Shortages  Current Drug Shortages Index Current Drug Shortages Index  Current Drug Shortages A - D Current Drug Shortages A - D  Current Drug Shortages E - K Current Drug Shortages E - K  Current Drug Shortages L - N Current Drug Shortages L - N  Current Drug Shortages O - R Current Drug Shortages O - R  Current Drug Shortages S - Z Current Drug Shortages S - Z  Resolved Drug Shortages Resolved Drug Shortages  Drugs to be Discontinued Drugs to be Discontinued  How to Report a Shortage or Supply Issue How to Report a Shortage or Supply Issue  Frequently Asked Questions About Drug Shortages Frequently Asked Questions About Drug Shortages

 A  Acetylcysteine Inhalation Solution1 10/15/2012 Alfentanil Injection2 (initial posting 1/23/2012) Amikacin Injection3 Amino Acid Products4 (initial posting 2/14/2012) 10/15/2012 Ammonium Chloride Injection5 Ammonul (sodium phenylacetate and sodium benzoate) Injection 10%/10%6 (initial posting 9/18/2008) Amphetamine Mixed Salts, ER Capsules7 (initial posting 10/31/2011) Amphetamine Mixed Salts Immediate-Release Tablets8 (initial posting 1/12/2012) Aquasol A9 Atracurium besylate10 (initial posting 2/27/2012) Atropine Sulfate Injection11 Acetylcysteine Inhalation Solution Alfentanil Injection Amikacin Injection Amino Acid Products Ammonium Chloride Injection Ammonul (sodium phenylacetate and sodium benzoate) Injection 10%/10% Amphetamine Mixed Salts, ER Capsules Amphetamine Mixed Salts Immediate-Release Tablets Aquasol A Atracurium besylate Atropine Sulfate Injection

8Community Oncology Alliance

Atropine  Shortage per Manufacturer: American Regent/Luitpold has discontinued manufacturing the ampoules  Product will be made available as it is released.Shortage per Manufacturer: Increase in product demand.  Shortage per Manufacturer: Increase in product demand caused by market supply issues.  Please check with your wholesaler for available inventory. Shortage per Manufacturer: Manufacturing delay

The When? Medicare Modernization Act (MMA) Few if any shortages prior to 2003 Reimbursement set at 6 % of ASP Unintended consequence of legislation

The Where? Community Oncology Clinics Over 80 % of cancer patients treated Hospital/Academic cancer clinics have protection under 340B for pricing but suffer same challenges of drug shortages.

The Why?  Cause of Drug shortages is economic  Majority of drug shortages occur where profitability is low  AWP + 6% can be less than the cost to give the drug  Manufacturing Pressures, Quality, Regulation, Cost  Race to the bottom in cutting costs

WHO? Patients Physician staff Pharma Politicians Brenda

Brenda’s Story

Brenda’s Chemotherapy Shortage Diagnosed in 1996 with Breast Cancer rx’ed lumpectomy and XRT BRCA 1 positive, mother died from breast cancer Stage III ovarian cancer in 5/2006 Carbo, taxotere, gemcitabine, topotecan, cisplatin, Doxil started 11/2010 with good control of disease

Doxil unavailable, 8/2011 Doxil unavailable 8-11 Progressive disease and admitted with bowel obstruction, Liposomal Doxorubicin from India available and rx’ed , with control of disease

Doxil Shortage  Janssen Products, LP (formerly Centocor Ortho Biotech Products, L.P.) (1-800-JANSSEN)Doxil 2 mg/mL, Janssen Products, LP 2 mg/mL, 10 mL (20 mg) vial (NDC ) Please see mber2011.pdf28 29 for additional information. mber2011.pdf  Important Updates on DOXIL Supply Shortage Important Updates on DOXIL Supply Shortage  Shortage per Manufacturer: Manufacturing delays

URGENT – Doxil® (Doxorubicin Hydrochloride Liposome Injection) Shortage Update January 27, 2012 Dear Healthcare Professional  At this time, FDA’s regulatory discretion for the importation and distribution of Sun Pharma’s LipodoxTM (Doxorubicin Hydrochloride Liposome Injection) is limited to Sun Pharma Global FZE and its authorized distributor, Caraco Pharmaceutical Laboratories Ltd, during the critical shortage of Doxil.

21Community Oncology Alliance

Medical Roller Coaster

Chemotherapy Drug Shortages What? 122 Drugs/12 Cancer When? 2003 Where? Everywhere Why? Economic Who? Brenda

Prognosis of Drug Shortage The condition is serious caused by multiple factors the greatest of which is economic. Low profitability on generic manufactured drugs will to discourage production. Pressure or enticement to ensure adequate drug supply is necessary

Solutions(Or why it isn’t as bad as it seems)  Drugs from India: Doxil  Legislation: FDA Safety and Innovation Act  Robust options for treatment  Health-care professionals have been sharing resources and supplies of various drugs including those used in chemotherapy treatment  Gray Market/Stockpiling fraud control  Obligation by Pharma to produce drugs at reduced margins

Drug Shortages Provisions in Public Law No: , FDA Safety and Innovation Act  On July 9, 2012 President Obama signed into law legislation  Notification Requirements  Expedited Inspections and Reviews  Repackaging guidance  Reports, Strategic Plan and Study

27Community Oncology Alliance

28Community Oncology Alliance

29Community Oncology Alliance

30Community Oncology Alliance

32